STOCKS TELEGRAPH

Tag: CNSP

  • CNS Pharmaceuticals Inc. (CNSP) stock Plunges After Hours Following FY2021 Results

    CNS Pharmaceuticals Inc. (CNSP) stock Plunges After Hours Following FY2021 Results

    On March 03, CNS Pharmaceuticals Inc. (CNSP) announced its financial results for Q4 and fiscal 2021 along with corporate updates. In the following after-hours session, the stock plunged down while it added 10.14% during regular trading.

    At a volume of 11 million shares, the stock fluctuated between a high of $0.3725 and a low of $0.3100 in the regular session. CNSP closed the session in the green at $0.3650, adding $0.0336 or 10.14%. The session’s volume remained 945% of its average 1.16 million shares. Following the gain, the stock suffered a loss of 6.88% in the after-hours session. Thus, CNSP was trading at $0.3399 apiece at an after-hours volume of 3.7 million on Thursday.

    The pre-clinical stage pharmaceutical company, CNS Pharmaceuticals Inc. has a market capitalization of $9.25 million. Currently, the company has 27.92 million shares outstanding in the market. In the past five days, the stock has increased by 14.78% while losing 48.04% year to date. Moreover, CNSP lost a value of 83.78% last year.

    CNSP’s 2021 Financials

    The company incurred a net loss of $14.0 million in fiscal 2021, against $9.5 million in the previous year.

    Furthermore, the R&D expenses were $9.3 million in fiscal 2021, while the same was $5.1 million in fiscal 2020.

    CNSP reported G&A expenses of $4.7 million in 2021 against that of $4.4 million in the previous year.

    Finally, the company ended the year with cash of $5.0 million and $5.3 million on working capital, on December 31, 2021.

    Corporate Updates

    Some of the key highlights of 2021 include:

    • In May 2021, the company initiated enrollment of patients in the CNS-201 study for Berubicin in recurrent Glioblastoma Multiforme.
    • In June 2021, Berubicin was granted Fast Track Designation for rGBM.
    • In September 2021, the dosage of patients started in the CNS-201 study.
    • In December 2021, approval from “swissethics” was received for Berubicin rGBM study in Switzerland.
    • CNSP’s Recent Participation
    Source: Pharmaphorum

    In January, the company participated in the Virtual Investor 2022 Top Picks Conference. CNSP’s CEO, John Climaco participated in the conference on Wednesday, January 26, 2022.

    Private Placement

    On January 06, the company announced an at-the-market private placement of 12,105,264 common stock shares and warrants. Further, the purchase price of each share and the associated warrant was $0.95 with gross proceeds of $11.5 million approximately.

    Thus, with an exercise price of $0.82 per share, the warrants were exercisable immediately upon issuance.

    Therefore, on January 10, CNSP announced the closing of the private placement for gross proceeds of $11.5 million.

  • CNS Pharmaceuticals Inc. (CNSP) stock Rebounds in the After Hours

    CNS Pharmaceuticals Inc. (CNSP) stock rebounded in the after-hours on Friday, to add 12.47% at $0.79. Hence, the stock entered the new year in the green, while it had been trading in the red for some time now.

    During the regular session, the stock saw a decline of 7.49% at its close of $0.7024 on Friday. The stock rebounded in the after-hours to recover more than it lost during the regular session. Consequently, CNSP was trading at $0.7900 apiece at a volume of 42.63K shares in the after hours.

    In the past five days, the stock has lost 19.01% and over 29.4% last month. Moreover, the stock has subtracted a value of 52.54% in the past three months and 60.54% in 2021.

    Currently, the 27.92 million outstanding shares of the biopharmaceutical company trade at a market capitalization of $19.61 million.

    CNSP’s Approval from Switzerland Ethics Committee

    On December 02, the company announced approval from swissethics for its pivotal study of Berubicin. Swissethics is the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland. Moreover, approval was received for the study of the product in treating recurrent glioblastoma multiforme (GBM). GBM is one of the most aggressive forms of brain cancer.

    The trial will be an adaptive, multicenter, open-label, randomized, and controlled study in GBM patients after standard first-line therapy failure. Moreover, the primary endpoint of the study is Overall Survival.

    In addition, CNSP hopes to expand the pivotal study to more sites throughout the world.

    Berubicin

    Berubicin is an anthracycline, which is one of the most effective chemotherapy drugs. Recently, Berubicin was granted Fast Track Designation by the FDA. Moreover, it has also received Orphan Drug Designation from the FDA, allowing for up to seven years of marketing exclusivity to CNSP, upon NDA approval.

    Recent Participation

    As per November 16’s announcement, the company recently participated in the Virtual Investor Roundtable Event. CNSP’s CEO, John Climaco, and CMO, Sandra L. Silberman participated in the event which took place on November 18, 2021.

    CNSP’s Financials

    The company declared its financial results for the first half of 2021 on August 13, 2021.

    In the first half of 2021, CNSP incurred a net loss of $3.8 million, against $2.4 million in the year-ago period.

    Moreover, the company ended the first half of 2021, with cash and subscription receivable (fully collected on July 1) of $10.5 million. Furthermore, the working capital at the end of the period was $12.1 million approx.

  • Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today?

    Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today?

    Shares of the CNS Pharmaceuticals, Inc. (CNSP) stock were climbing in the Pre-market today on June 18, 2021, following the announcement made by CNS pharmaceuticals yesterday that it has been selected to be included in Russell 2000® Index. The CNSP stock price saw a push of 4.00% to reach $2.08 a share at the time of this writing. CNSP stock climbed 3.09% at the previous closing. Let’s take a closer look at current happenings.

    What’s Happening?

    CNS Pharmaceuticals, Inc, founded in 2017, develops the anticancer drugs that are used to treat brain and central nervous system tumors. CNSP addition in Russell 2000® Index would be effective from after closing of U.S. equity markets on June 25, 2021. This inclusion would help the CNSP stock to drive market awareness for its clinical program in the fight against glioblastoma multiforme (GBM) disease.

    The Russell 2000® Index is the subset of the Russell 3000® Index in which  2,000 smallest securities based on current index membership and market cap combination are added. It evaluates the performance of these smallest securities and constitutes  10% of the total market capitalization of its parent index.

    Patient Enrollment:

    Back to the previous month on May 19, 2021, CNSP stock did announce the commencing of patient enrollment in its potential pivotal study that was intended to evaluate the efficacy as well as safety of Berubicin when it is used to treat adult recurrent Glioblastoma Multiforme (GBM). The CNS pharmaceuticals planned 210 patients in its 35 clinical sites in the United States and also expressed the wish to extend the trial in Western Europe. The primary endpoint for the study was overall survival.

    Financial View of CNSP stock:

    On May 14, 2021, CNSP stock released its first-quarter 2021 financial results according to which a $3.6 million net loss was reported higher than $2.0 million in the same quarter of the previous year. Research and development expenses increased by $1.6 million in the recently reported quarter to reach $2.2 million as compared to the same prior-year period. The quarter ended with $11.0 million cash and cash equivalents which according to CNSP stock’s management is enough to fund operation during the current year.

    Conclusion:

    The CNSP stock is continuing the rising momentum after the announcement of its selection in the Russell 2000® Index. The stock is growing with time and has enough cash to fund its operations for next year. Hence investors need to keep this stock on their books.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.